Literature DB >> 6302123

Effects of cyproheptadine, reserpine, and synthetic corticotropin-releasing factor on pituitary glands from patients with Cushing's disease.

T Suda, F Tozawa, T Mouri, A Sasaki, T Shibasaki, H Demura, K Shizume.   

Abstract

Direct effects of cyproheptadine, reserpine, synthetic ovine corticotropin-releasing factor (CRF), dexamethasone, and lysine-8-vasopressin (LVP) on the secretion of immunoreactive ACTH and beta-endorphin from the adenoma and the nonadenomatous tissue of patients with Cushing's disease were examined using a superfusion system. Cyproheptadine and reserpine (10(-9)-10(-7) M of each) suppressed immunoreactive ACTH and beta-endorphin secretion from both tissues. CRF (10(10)-10(7) M) stimulated the secretion of both peptides from the nonadenomatous tissue, but only a high dose of CRF could stimulate the secretion of these peptides from some adenomas. Such CRF-induced secretion was partially suppressed by dexamethasone. LVP (10(-9)-10(-7) M) stimulated peptide secretion from both types of tissue. These results suggest direct inhibitory effects of cyproheptadine and reserpine on the secretion of these peptides from the pituitary of patients with Cushing's disease, a different stimulatory mechanism of LVP from that of CRF in these tissues, and low sensitivity of the adenoma to CRF.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302123     DOI: 10.1210/jcem-56-6-1094

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  9 in total

Review 1.  Molecular basis of pharmacological therapy in Cushing's disease.

Authors:  Diego Ferone; Claudia Pivonello; Giovanni Vitale; Maria Chiara Zatelli; Annamaria Colao; Rosario Pivonello
Journal:  Endocrine       Date:  2013-11-23       Impact factor: 3.633

2.  Long-term culture of human corticotropin-secreting adenomas on extracellular matrix and evaluation of serum-free conditions. Secretory aspects.

Authors:  M Westphal; P Jaquet; C B Wilson
Journal:  Acta Neuropathol       Date:  1986       Impact factor: 17.088

Review 3.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

4.  Cushing's syndrome caused by an ectopic pituitary adenoma of the sphenoid sinus: Adrenal crisis after partial resections of the adenoma.

Authors:  Hiroyuki Morita; Keigo Yasuda; Kazuya Nkashima; Nobuyasu Noritake; Masanori Murayama; Kuniyasu Shimokawa; Noriyoshi Yamakita; Toshiaki Sano; Nobuaki Sasano; Kiyoshi Miura
Journal:  Endocr Pathol       Date:  1994-06       Impact factor: 3.943

Review 5.  Medical management of pituitary adenomas: structural and ultrastructural changes.

Authors:  Sylvia L Asa; Shereen Ezzat
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

6.  Cyproheptadine treatment in Cushing's disease.

Authors:  R Tanakol; F Alagöl; H Azizlerli; O Sandalci; T Terzioğlu; F Berker
Journal:  J Endocrinol Invest       Date:  1996-04       Impact factor: 4.256

7.  Cyproheptadine may act at the pituitary in Cushing's disease: evidence from CRF stimulation.

Authors:  J R Tucci; K J Nowakowski; I M Jackson
Journal:  J Endocrinol Invest       Date:  1989-03       Impact factor: 4.256

8.  Effects of corticotropin-releasing hormone and dexamethasone on proopiomelanocortin messenger RNA level in human corticotroph adenoma cells in vitro.

Authors:  T Suda; F Tozawa; M Yamada; T Ushiyama; N Tomori; T Sumitomo; Y Nakagami; H Demura; K Shizume
Journal:  J Clin Invest       Date:  1988-07       Impact factor: 14.808

Review 9.  Pituitary-Directed Therapies for Cushing's Disease.

Authors:  Fabienne Langlois; Jennifer Chu; Maria Fleseriu
Journal:  Front Endocrinol (Lausanne)       Date:  2018-05-01       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.